drugset / Trial / NCT05301764
A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to asess the safety and tolerability and efficacy of LVGN6051 combined with anlotinib in patient with soft tissue sarcoma.
Timeline
- Start
- 2022-05-25
- Primary completion
- 2025-12-19
- Completion
- 2025-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | EXLINKIBART | Monoclonal antibody | — | Intravenous |